Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of calcitonin salmon spray in China. Welcome to wholesale bulk high quality calcitonin salmon spray for sale here from our factory. Good service and reasonable price are available.
Calcitonin salmon spray (salmon calcitonin nasal spray) is a synthetic polypeptide hormone drug, mainly used to treat diseases related to abnormal bone metabolism. It reduces ossature calcium release by inhibiting osteoclast activity, thereby lowering blood calcicat levels, while stimulating osteoblast formation and enhancing ossature strength. It can also be used to treat high turnover ossature diseases such as Paget's disease. Administered through nasal cavity, convenient to use, with mostly mild and tolerable adverse reactions such as nausea, facial flushing, etc., which usually do not affect treatment.
Calcitonin Salmon COA
 |
||
| Certificate of Analysis | ||
| Compound name | Calcitonin salmon | |
| Grade | Pharmaceutical grade | |
| CAS No. | 47931-85-1 | |
| Quantity | 80g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090056 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.31% |
| Loss on drying | ≤1.0% | 0.62% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.80% |
| Single impurity | <0.8% | 0.44% |
| Total microbial count | ≤750cfu/g | 209 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 512ppm |
| Storage | Store in a sealed, dark, and dry place below 2-8°C | |
|
|
||
| Chemical Formula: | C145H240N44O48S2 |
| Exact Mass: | 3430 |
| Molecular Weight: | 3432 |
| m/z: | 3431 (100.0%), 3432 (77.9%), 3430 (63.8%), 3433 (40.1%), 3432 (16.3%), 3433 (12.3%), 3431 (10.4%), 3433 (9.9%), 3433 (9.0%), 3434 (8.8%), 3434 (7.7%), 3434 (7.0%), 3434 (6.6%), 3432 (6.3%), 3432 (5.8%), 3434 (5.0%), 3435 (3.2%), 3435 (3.0%), 3435 (3.0%), 3432 (2.8%), 3433 (2.1%), 3432 (1.8%), 3431 (1.8%), 3435 (1.7%), 3434 (1.6%), 3432 (1.6%), 3434 (1.5%), 3434 (1.5%), 3433 (1.4%), 3435 (1.3%), 3433 (1.3%), 3433 (1.2%), 3435 (1.2%), 3431 (1.2%), 3435 (1.2%), 3435 (1.1%), 3433 (1.0%), 3431 (1.0%) |
| Elemental Analysis: | C, 50.75; H, 7.05; N, 17.96; O, 22.38; S, 1.87 |
Calcitonin salmon spray is an artificially synthesized calcitonin analogue that has a wide range of clinical applications, especially playing an important role in the treatment of hypercalcemia, painful neurotrophication (Sudeck's disease), and other conditions.
In the treatment of hypercalcemia
(1) Overview of hypercalcemia
Hypercalcemia refers to a pathological state in which the concentration of calcium ions in the blood is abnormally elevated, which can be caused by various reasons such as malignant tumor ossature metastasis, hyperparathyroidism, vitamin D poisoning, etc. The clinical manifestations of hypercalcemia are diverse, ranging from asymptomatic in mild cases to severe symptoms such as nausea, vomiting, polyuria, thirst, fatigue, arrhythmia, and even coma, which can be life-threatening. Therefore, timely and effective reduction of blood calcicat levels is crucial for improving patient prognosis.
(2) The mechanism of action for treating hypercalcemia
Inhibition of osteoclast activity: It can specifically bind to calcitonin receptors on the surface of osteoclasts, inhibit osteoclast osteolytic activity, reduce ossature calcium release into the blood, and thus lower the concentration of calcium ions in the blood. This is the main mechanism for reducing blood calcicat.
Promote renal excretion of calcium and phosphorus: Salmotonin can also promote renal excretion of calcium and phosphorus, increase urinary calcium and phosphorus excretion, and further reduce blood calcicat levels.
Regulating parathyroid hormone secretion: It has a certain inhibitory effect on parathyroid hormone, which can reduce its secretion, thereby reducing its stimulation on ossatures and kidneys.
Reducing the release of ossature calcium and the reabsorption of calcium by renal tubules, and helping to lower blood calcicat.
(3) Indications for treating hypercalcemia
Hypercalcemia due to ossature metastasis of malignant tumor: Hypercalcemia secondary to ossature metastasis of breast cancer, lung cancer, kidney cancer, myeloma and other malignant tumors is one of the common indications of salmotonin. Malignant tumor cells invade ossatures, destroy ossature tissue, and cause a large amount of ossature calcium to be released into the bloodstream, leading to hypercalcemia. It can quickly reduce blood calcicat levels, alleviate symptoms such as polyuria, thirst, nausea, vomiting caused by high blood calcicat, and improve the quality of life of patients.
Hyperparathyroidism: Hyperparathyroidism is caused by excessive secretion of parathyroid hormone, leading to increased release of ossature calcium and increased reabsorption of calcium by renal tubules, resulting in hypercalcemia. It can alleviate symptoms such as ossature pain and skeletal deformities caused by hyperparathyroidism by inhibiting osteoclast activity and promoting renal excretion of calcium and phosphorus, reducing blood calcicat levels.
Vitamin D poisoning: Vitamin D poisoning can lead to increased absorption of calcium in the intestine and elevated blood calcicat levels. It can inhibit ossature calcium release and promote kidney calcium excretion, helping to reduce blood calcicat and alleviate symptoms caused by vitamin D poisoning. Both acute and chronic poisoning can be treated with salmotonin.
(4) Usage and dosage for treating hypercalcemia
The usage and dosage of its treatent for hypercalcemia need to be adjusted according to the specific situation of the patient. Generally speaking, for patients with hypercalcemia, subcutaneous or intramuscular injections can be administered once or twice a day, and multiple site injections should be taken to reduce local irritation. During the treatent process, the dosage should be adjusted in a timely manner based on the patient's clinical and biochemical reactions, such as blood calcicat levels and symptom improvement.
For patients with acute hypercalcemia crisis, intravenous injection or intravenous drip can be used to lower blood calcicat levels more quickly. However, it should be noted that the effect of lowering blood calcicat is limited. For patients with severe hypercalcemia, it is usually necessary to use it together with bisphosphonates to achieve better results in lowering blood calcicat.
(5) Evaluation of the therapeutic effect of treating hypercalcemia
Multiple clinical studies have shown that it can quickly and effectively reduce blood calcicat levels in patients with hypercalcemia. Generally speaking, within a few hours to a few days after medication, blood calcicat levels can begin to decrease and symptoms can be relieved.
For example, for patients with hypercalcemia caused by malignant tumor ossature metastasis, treatent with calcitonin salmon spray can significantly reduce blood calcicat levels in a short period of time, alleviate symptoms such as polyuria, thirst, and nausea, and improve the patient's quality of life. At the same time, the safety of treating hypercalcemia is relatively high, and the adverse reactions are mostly mild and tolerable, such as facial flushing, nausea, vomiting, etc., which usually occur in the early stages of medication and can gradually alleviate or disappear with prolonged medication time.
Source of information:
The information about the use of salmotonin in the treatment of hypercalcemia mainly comes from the following literature and websites:
The role and efficacy of salmotonin released by Medical Alliance Media (Yikang Media).
The function of salmotonin released by Minfukang (Huai'an Minfukang Technology Co., Ltd.).
Family doctors have released an online article titled 'The Effects of Salmotonin Injection'.
39 Medication (39 Health Network) released "What are the effects of injectable salmotonin.
The China Medical Information Query Platform has released the document "Salmotonin Injection - The Effect of Salmotonin Injection - The Usage and Dosage of Salmotonin Injection - Adverse Reactions of Salmotonin Injection | China Medical Information Query Platform".
In the treatment of painful neurotrophication (Sudeck's disease)
(1) Overview of Painful Neurodystrophy (Sudeck's Disease)
Painful Neurodystrophy, also known as Sudeck's disase, is a disase characterized by pain, swelling, changes in skin temperature, and osteoporosis. It often occurs after trauma to the upper or lower limbs and can also be caused by other reasons such as fractures, surgery, infections, etc. The pathogenesis of this disase is not fully understood, and it is currently believed to be related to factors such as neurogenic inflammation, sympathetic dysfunction, and osteoporosis.
Patients often present with severe pain, local swelling, increased or decreased skin temperature, limited joint movement, and other symptoms, which seriously affect their quality of life.
(2) The mechanism of action for treating Sudeck's disease
Inhibiting osteoclast activity and reducing ossature loss: Patients with painful malnutrition often have osteoporosis, and salmotonin can inhibit osteoclast activity, reduce ossature loss, increase ossature density, improve ossature microstructure, enhance ossature strength, and reduce pain caused by osteoporosis.
Inhibiting the release of inflammatory mediators and reducing inflammatory reactions: It has anti-inflammatory effects and can inhibit the release of inflammatory mediators such as prostaglandins and leukotrienes, alleviate local inflammatory reactions, and relieve pain and swelling symptoms.
The effect on nerve endings: It can also directly act on nerve endings, inhibit the transmission of nerve impulses, reduce nerve sensitivity, and thereby alleviate pain.
(3) Indications for the treatment of Sudeck's disease
Mainly used for the treatent of early diagnosed painful neurotrophication (Sudeck's disase).
Once diagnosed, it should be used for treatent as early as possible to control the progression of the disase, alleviate symptoms, and improve the patient's quality of life. For similar disases caused by other etiologies and triggers, such as post-traumatic painful osteoporosis, reflex neurotrophication, shoulder arm syndrome, burning pain caused by peripheral nerve injury, drug-induced neurotrophication, etc., it also has certain therapeutic effects.
(4) Evaluation of the therapeutic effect on Sudeck's disease
Clinical studies have shown significant therapeutic effects on Sudeck's disease.
After medication, the patient's pain symptoms can be significantly relieved, local swelling gradually subsides, skin temperature returns to normal, joint mobility increases, and quality of life is significantly improved.
For example, a study found that after 4 weeks of treatent for patients with painful malnutrition, their pain scores significantly decreased, swelling levels significantly reduced, and joint range of motion increased. At the same time, calcitonin salmon spray has a high safety profile in treating painful malnutrition, with mostly mild and tolerable adverse reactions such as facial flushing, nausea, injection site reactions, etc., which usually do not affect the continuation of treatment.
Source of information:
Medical Alliance Media (Yikang Media) released "The Role and Efficacy of Salmotonin".
Minfukang (Huai'an Minfukang Technology Co., Ltd.) has released "The Effect of Salmotonin".
39 Medication (39 Health Network) released "What are the effects of injectable Salmotonin.
The China Medical Information Query Platform has released the document "Salmotonin Injection - The Effect of Salmotonin Injection - The Usage and Dosage of Salmotonin Injection - Adverse Reactions of Salmotonin Injection | China Medical Information Query Platform".
Baidu Baike has released "Salmotonin".
Hot Tags: calcitonin salmon spray, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale